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Abstract
Background: In this paper we study the distribution of leukocyte populations and of cytokine-producing cells in
the spleen of a patient with visceral leishmaniasis resistant to clinical treatment. It is the first attempt to compare
the distribution of leukocyte populations and cytokine-producing cells in the splenic compartments of a patient
with visceral leishmaniasis with those observed in patients without the disease.
Case presentation: A 25-year-old male, farmer, was hospitalized on several occasions with diagnosis of visceral
leishmaniasis and received all recommended treatments for the disease with only transient improvement followed
by relapse. He was eventually subjected to splenectomy in order to control the effects of hypersplenism and to
potentially overcome infection. After surgery and combined chemotherapy, the disease evolved to cure. In comparison
with the spleens of the other two patients without visceral leishmaniasis, an increase was observed in the CD4/CD8
ratio and in the number of IL-10- and FoxP3-producing cells, while the number of IL-17-producing cells was lower in
the spleen of the patient with visceral leishmaniasis.
Conclusion: This report confirms previous data on changes in the CD4/CD8 ratio in the spleens of patients with
visceral leishmaniasis. Additionally the data presented herein suggests that splenic FoxP3- and IL-17-producing cells are
involved in the chronicity of visceral leishmaniasis.
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Background
Visceral leishmaniasis is an infectious disease caused by
an intracellular parasite of the species Leishmania infan-
tum or Leishmania donovani [1]. In vertebrate hosts, the
parasite lives in the mononuclear phagocytes of a variety
of tissues, mainly the liver, spleen, bone marrow and
lymph nodes [2]. Visceral leishmaniasis is character-
ized by hepatomegaly, splenomegaly, fever, emaciation,
anemia and an increased susceptibility to bacterial in-
fection and bleeding [3]. Most patients with visceral
leishmaniasis respond to treatment with antimonials,
or with second-line therapeutics, such as pentamidine
or amphotericin [4]. However, some patients present
multiple relapses, resulting in the failure of conven-
tional therapeutic intervention [5]. In some of these
cases, splenectomy can be performed as a final thera-
peutic attempt [5]. The literature contains few reports
of therapeutic spleen removal in visceral leishmaniasis,
and little is known about the mechanism involved in
the control of infection obtained via splenectomy [6].
Among the putative contributing factors associated with
splenectomy in patients with visceral leishmaniasis are the
reduction of parasite burden and the suppression of
hypersplenism, which may cause hematological abnor-
malities [5].
In this study, the distribution of leucocyte populations
and of cytokine-producing cells was investigated, using
immunohistochemistry, in the spleen of a patient who
steadily progressed to cure following splenectomy, per-
formed as a final attempt to treat visceral leishmaniasis.
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For comparison purposes, splenic samples were selected
from the archives of the Service of Anatomopathology of
Aliança Hospital, Salvador, Brazil (a non-endemic area
of visceral leishmaniasis), obtained from two patients
subjected to splenectomy, one during the surgery to re-
move a non-lymphoid, benign pancreatic neoplasia and
another due to trauma in a car accident.
Four-μm thick splenic tissue sections were stained
with hematoxylin and eosin. Immunohistochemistry was
also performed using the following antibodies: CD3
(policlonal rabbit), CD4 (4B12), CD8 (C8/144B), CD20
(L26), CD79 (JCB117), CD138 (MI15), all from Dako
(Glostrup, Denmark) as well as a homemade polyclonal
anti-Leishmania antibody [7]. Deparffinization and anti-
gen retrieval was performed using a Dako PT Link
(PT100/PT101) high pH module at 97°C for 20 minutes.
The DAKO EnVision + HRP kit (Dako Co, Denmark)
was used as an amplification system. Diaminobenzidine
was used as the chromogen. Sections were counter-
stained with haematoxylin. Mouse IgG1 isotypes unre-
lated to the antigens were used as a negative control to
replace the primary antibody. Cytokine detection was
performed using these primary antibodies: MAB 285
(IFNγ), AF-210-NA (TNFα), AF-217-NA (IL10), AF-
206-NA (IL6), AF-317-NA (IL17) and AF-204-NA (IL4)
(RD Systems), as well as 14-4776-82 (Foxp3 from E-
Bioscience), in accordance with the following protocol:
Deparaffinization and rehydration were performed in xy-
lene, followed by a decreasing series of ethanol solutions
and the blockage of endogenous tissue peroxidase in 3%
hydrogen peroxide. Antigen unmasking was performed
using a heat-induced antigen retrieval method in a water
bath with Retrieval Buffer (Dako Corporation, Carpinteria
CA, USA) for 25 minutes at 95°C, pH 9.0. Next, the sec-
tions were incubated in a saponin solution (0.1% in PBS
0.01 M, pH7.4) for 10 minutes at room temperature,
Table 1 Laboratory data of the patient with visceral leishmaniasis before (7/28/2009 to 4/10/2012) and after
(5/15/2012) splenectomy
LABORATORY DAY
TEST 7/28/2009 8/19/2010 1/13/2011 5/13/2011 1/12/2012 4/10/2012 5/15/2012
Hematocrit 31 36 36 24 21 27 38
Hemoglobin 9.1 11.7 11.9 8.2 6.6 8.2 11
WBC count 2100 2360 2500 2380 1410 2280 5500
Lymphocyte count 588 1133 1200 1261 705
Platlet count 136000 185000 210000 150000 154000 70300 570000
Urea 31 23 22 31 32 38
Creatinine 1.1 0.9 0.8 1.2 1,3 1,4
ALT 20 41 59 54
AST 32 10 25 17
ESR (1 h/2 h) 80/110 109/124 50/70
CRP R NR NR
Bilirrubin (direct) 0.7 (0.3) 1.0 (0.5) 0.8 (0.4)
Total Protein 9.2 5.2 8.6 7.1
Albumin 2.9 3.5 2.8 3.2
PT/P activity 41 s/22% 18 s/54% 28 s/29% 14.6 s/75%
RNI 1.9 1.47 2.12 1.15
Glucose 69 79 93
ALP 80 176 213
GGT 68
Rapid test for HIV NR NR NR
Leishmania search in bone marrow smears POS POS POS POS POS NEG NEG
Rapid test for VL POS POS NEG NEG NEG
IFR for Leishmania 1/160 NEG
HAV NEG
HCV POS NEG
HBsAg NEG NEG
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Figure 1 (See legend on next page.)
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followed by incubation in skim milk 10% for 30 minutes
and a final incubation with the primary antibodies di-
luted in 1% bovine albumin – PBS solution, overnight
at 4°C. Specific antibody binding was detected using a
second antibody and the LSAB system (Dako Corpor-
ation, Carpinteria CA, USA, K690) for 30 minutes at
37°C. All reactions were developed using a 3′3 diamino-
benzidine chromogen solution and counterstained with
Harris hematoxilin.
Case presentation
A 25-year-old farmer, male, suffered from recurrent epi-
sodes of fever and asthenia, mucocutaneous pallor and
abdominal distention. He was hospitalized on several
occasions between 2009-2011 with a consistent diagno-
sis of visceral leishmaniasis, as confirmed by laboratory
testing including the finding of amastigotes of the para-
site in bone marrow smears. The patient received all
recommended treatments for American visceral leish-
maniasis, including pentavalent antimony (Gloucantime®),
amphotericin B and pentamidine with only transient
symptomatic improvement followed by relapse. He was
eventually admitted to the Getúlio Vargas Hospital
(Teresina, Piauí State, Brazil) in January 2012. Clinical
examination revealed mucocutaneous pallor (2+/4+),
fever (38.5°C), dehydration (2+/4+), a distended abdo-
men with mild pain upon deep palpation and spleno-
megaly (8 cm below the left costal margin). Laboratory
tests detected anemia, leucopenia, hypergammaglobu-
linemia and high levels of ESR and CRP (Table 1). On
May 2, 2012, a splenectomy was performed to control
the effects of hypersplenism and to potentially over-
come infection. After surgery and combined chemo-
therapy, the disease evolved to cure and the patient
remained asymptomatic with improvement observed
in laboratory parameters (Table 1). The Leishmania
isolates were investigated with respect to resistance to
the antiparasitic drugs Glucantime, amphotericin and
pentamidine, with no resistance pattern observed.
The spleen weighed 1,860 g, and measured 25.0 × 17.0 ×
9.0 cm. The capsule was thin and transparent. The cut
surface was deep red with areas of necrosis and
hemorrhage. Histologically, the white pulp was well-
organized with large-sized secondary lymphoid follicles
surrounded by well-defined marginal zones (Figure 1A).
The periarteriolar lymphoid sheaths (PALS) were clearly
evident. The red pulp was hyperplastic with prominent
cords, dilated sinusoids and an increased amount of
fusiform cells. Amastigotes containing macrophages,
small aggregates of plasma cells, occasional erythro-
cytes containing macrophages, as well as ill-defined
granulomas with infected macrophages, were observed
among the splenic cords (Figure 1B and insert).
Along with the spleen, a perisplenic lymph node col-
lected during the surgery was received. The lymph node
measured 1.2 × 0.7 cm. The lymph node capsule was in-
filtrated by lymphocytes and Leishmania-infected mac-
rophages. The lymph node structure was normal, the
marginal sinus contained few lymphocytes and the
lymphoid follicles were mostly small with germinal cen-
ters (not shown). The paracortical areas were expanded
and partially replaced by large amastigote-containing
macrophages, which were also seen in the interior of the
follicles and germinal centers. The medullary cords and
medullary sinus were barely evident, containing many
plasma cells and infected macrophages (not shown).
Control #1: A 42-year-old female had her spleen
removed in the course of a surgery to resect a solid
pseudopapillary (benign) pancreatic tumor. The spleen
weighed 83.0 g and measured 10.5 × 6.0 × 3.0 cm.
Spleen sections showed small lymphoid follicles with
small germinal centers and the mantle zones were not
uniformly apparent. Some follicles showed hyalinosis.
The red pulp had a predominance of macrophages and
lymphocytes with some neutrophils present. Some arte-
rioles presented hyaline arteriolosclerosis (Figure 1J).
Control #2: A 31-year-old male underwent splenec-
tomy 3 h after suffering traumatic spleen rupture due to
a car accident. The spleen weighed 133 g and measured
10.0 × 7.0 × 3.8 cm. Spleen sections showed a large area
of recent hemorrhage, surrounded by normal spleen par-
enchyma. The lymphoid follicles were small, had small
germinal centers, and the mantle zones were not consist-
ently evident. The red pulp sinus were dilated and the red
pulp contained many reticular cells, macrophages, lym-
phocytes and neutrophil aggregates. Some arterioles pre-
sented hyaline arteriolosclerosis (Figure 1R).
The distribution of the leukocyte populations identi-
fied by immunohistochemistry shown in Figure 1 was
similar to what is described in the literature [8] in all
three cases studied. Immunohistochemistry revealed
very few isolated mononuclear cells producing IFN-γ
(Figure 2A-C), IL-4 (Figure 2D-F), IL-10 (Figure 2G-I)
and TNF-α (Figure 2M-O), mostly in the red pulp. A large
(See figure on previous page.)
Figure 1 Parasitism, histological changes and leukocyte populations in the spleen of a patient with chronic relapsing visceral
leishmaniasis (A-I) and of two control patients without the disease (J-Q, control #1; R-Y, control #2): A: large secondary follicles;
B: ill-formed granuloma; insert: amastigote-containing macrophages. Leukocyte populations: C, K, S: CD68+ macrophages; D, L, T: CD3+ T
lymphocytes; E, M, U: CD4+ T lymphocytes; F, N, V: CD8+ T lymphocytes; G, O, W: CD20+ B lymphocytes; H, P, X: CD79α + B lymphocytes; I, Q, Y:
CD138+ plasma cells. (figures A, J and R, bar = 600 μm; figures B-I, K-Q and S-Y, bar = 300 μm).
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Figure 2 Cytokine-producing cells in the spleen of a patient with chronic relapsing visceral leishmaniasis, as well as two control
patients: A-C: IFNγ; D-F: IL4; G-I: IL-10; J-L: IL-6; M-O: TNFα; P-R: IL17; S-U: Fox-P3. (bar = 30 μm).
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number of IL-6 (Figure 2J-L) and IL-17 (Figure 2P-R)-pro-
ducing cells were observed in the red pulp and in the
PALS. Fox-P3 (Figure 2S-U)-expressing cells were found
in the red pulp, PALS and in marginal zones.
Compared to the spleens of the other two patients, the
spleen of the patient with visceral leishmaniasis had in-
creased numbers of: macrophages in the lymphoid folli-
cles, CD4 T cells in the red pulp (Figure 1E compare
with 1M and 1U), B cells in the follicles and in the mar-
ginal zones (Figure 1G and H, compare with 1O-P and
1W-X), and plasma cells in the red pulp and in the mar-
ginal zones (Figure 1I, compare with 1Q and 1Y). In
addition, the density of IL10-producing cells was higher
in the spleen of the patient with visceral leishmaniasis
(Figure 2G-I). This patient had generally fewer IL17-
producing cells (Figure 2P-R). The density of Fox-P3-
producing cells was higher in the red pulp of the patient
with visceral leishmaniasis in comparison to what was
observed in the other patients (Figure 2S-U).
To the best of our knowledge, the literature contains
only one other report by Nylén and collaborators [9] on
the distribution of leukocyte populations in the spleen,
as well as cytokine production by human splenocytes in
visceral leishmaniasis. In this study, the authors, using
flow cytometry and RT-PCR on splenic cell aspirate,
were not able to demonstrate an increased number of
Fox-P3 positive cells in the spleens of patients with
acute visceral leishmaniasis (with 2-3 weeks of duration).
By contrast, the patient reported herein had a chronic
form of visceral leishmaniasis that lasted for more than
three years. An increased density of IL10 and Fox-P3-
producing cells was observed in the red pulp, as well as
in the follicles and in the marginal zones in comparison
with the spleens of the patients without visceral leish-
maniasis. Hence, these findings suggest the possibility
that Fox-P3 cells also accumulate in chronic visceral
leishmaniasis, similar to what occurs in cutaneous leish-
maniasis and other chronic diseases. Conversely, the
density of IL-17-expressing cells was generally lower in
the spleen of patient with visceral leishmaniasis patient
in comparison to the spleens of the other two patients.
The high density of both IL-17- and IL-6-producing cells
observed in the spleens of all three patients was notable.
Such high IL-17 and IL-6 production in the spleen sup-
ports the notion that the spleen plays an important role in
the surveillance of blood-borne infections. In fact, IL-17,
together with IL-6, participate in an axis of inflammation-
promoting cytokines involved in the innate response to
bacteria and Leishmania [10,11]. Pitta and colleagues [12]
showed that peripheral blood mononuclear cells from
patients with visceral leishmaniasis produced lower
levels of IL-17 after stimulation with Leishmania anti-
gens than the cells of individuals resistant to the dis-
ease. These authors suggest that susceptibility to
visceral leishmaniasis may be associated with an im-
pairment in Th-17 cell differentiation upon stimulation
with IL-1β and IL-6. Nylén and colleagues [9] also ob-
served an increase in the CD4/CD8 ratio, which de-
creased in response to amphotericin treatment. In the
patient with visceral leishmaniasis presented herein,
the CD4/CD8 ratio was found to be higher in the dif-
ferent spleen compartments in comparison to the
other patients.
In addition to the findings described above, the
present case confirms extensive reports on plasmacytosis
in association with visceral leishmaniasis. Furthermore,
we have demonstrated that plasma cell accumulation is
more pronounced in the red pulp and in the marginal
zones, which suggests that some of these cells may not
reach normal maturation in the PALS.
Conclusion
This report confirms previous data on changes in the
CD4/CD8 ratio in the spleens of patients with visceral
leishmaniasis. It also suggests that splenic FoxP3- and
IL-17-producing cells are involved in the chronicity of
visceral leishmaniasis. The authors feel that the data pre-
sented herein may contribute to the understanding of
disease progression and host parasite interaction in se-
vere forms of visceral leishmaniasis.
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